Inclusion Criteria:

   - Participation in and completion of stipulated final follow-up periods for study NTI
   0302, NTI 0303, or other designated studies.

   - Have a Karnofsky Performance of > 50 at Baseline

   - Capable of self-administration of subcutaneous injections twice daily or availability
   of assistance from caregiver.

   - Ability to provide written informed consent or, if unable to provide, have a legal
   guardian or representative provide written informed consent.

   - For women of childbearing potential: a negative serum pregnancy test at Baseline

Exclusion Criteria:

   - Concurrent enrollment in any investigational drug or device study, other than NTI
   0302, NTI 0303, or other designated studies.

   - Systemic steroid use for any indication other than peritumoral brain edema.

   - Use or intended use of dexamethasone as an anti-emetic during study.

   - Clinical signs and symptoms of cerebral herniation.

   - Serious concomitant cardiovascular, pulmonary, renal, gastrointestinal or endocrine
   metabolic disease which could put the patient at unusual risk during study
   participation.

   - Confounding previous or concurrent neurological disorders that would interfere with
   adequate clinical evaluation.

   - Clinically significant head injury or chronic seizure disorder, if the condition
   results in functional impairment or is likely to interfere with
   evaluations.(Maintenance anticonvulsant therapy is allowed)

   - Central nervous system (CNS) infection.

   - Pregnancy, breastfeeding and/or refusal to practice birth control while in study, for
   women of childbearing potential.